ABLUMINUS Below the Knee (BTK) Drug Eluting Stent (DES) Registry (ABLUMINUS BTK) - First in Men
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Primary patency using duplex ultrasound at 6 months post-procedure
研究概览
简要总结
A prospective, single center, single arm non-randomized trial collecting safety and effectiveness data for the ABLUMINUS DES System to treat BTK lesions in subjects with CLI.
详细描述
The burden of limb loss as a result of peripheral arterial disease (PAD) is high and this problem is set to worsen globally with increasing prevalence of diabetes. Treatment of PAD in diabetic critical limb ischemia (CLI) primarily involves revascularisation of the limb. Angioplasty as a first line strategy of revascularization over surgical procedures has been adopted by most vascular centers.
Arterial blockages for diabetic CLI patients occur predominantly in below the knee arteries which can be challenging to treat effectively. This is due to the high incidence of arterial recoil after conventional balloon angioplasty due the natural tendency of the vessels to maintain their original shape and the high restenosis rates of calcified lesions.
To address these problems the novel ABLUMINUS DES system is specifically designed to withstand the mechanical recoil of diseased BTK arteries whilst delivering sirolimus to biologically inhibit restenosis.
This study postulates that the application of the ABLUMINUS DES system will be safe and will result in better vascular patency in BTK arteries for CLI patients.
The investigators aim to conduct a prospective, all comers, single arm, single centre registry of the ABLUMINUS DES system for the treatment of BTK disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is 21 years or older and has signed and dated the trial informed consent document (ICD)
- •Subject is willing and able to comply with the trial testing, procedures and follow-up schedule
- •Subject has chronic, symptomatic diabetic related lower limb ischemia, determined by Rutherford categories 4 to 6 in the target limb, with wound(s) confined to toes/forefoot
- •Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator
- •Intraoperative inclusion criteria
- •Occlusive target lesion(s) located in the tibioperoneal trunk, anterior tibial, posterior tibial and/or peroneal artery(ies).
- •Target lesion(s) must be at least 4cm above the ankle joint
- •Degree of stenosis ≥ 70% by visual angiographic assessment
- •RVD is between 2.5 - 3.75mm
- •Total target lesion length (or series of lesion segments) to be treated is > 200 mm
- •Target lesion(s) is located in an area that may be stented without blocking access to patent main branches
- •Treatment of all above the knee inflow lesion(s) is successful prior to treatment of the target lesion
- •Guidewire has successfully crossed the target lesion(s)
排除标准
- •Life expectancy ≤ 1year
- •Stroke ≤ 90 days prior to the procedure date
- •Prior or planned major amputation in the target limb
- •Previous surgery in the target vessel(s) (including prior ipsilateral crural bypass)
- •Previously implanted stent in the target vessel(s)
- •Failed PTA of target lesion/vessel ≤ 60 days prior to the procedure date
- •Heel gangrene
- •Subject has a platelet count ≤ 50 or ≥ 600 X 103/µL ≤ 30 days prior to the procedure date
- •NYHA class IV heart failure
- •Subject has symptomatic coronary artery disease (ie, unstable angina)
- •History of myocardial infarction or thrombolysis ≤ 90 days prior to the procedure date
- •Non-atherosclerotic disease resulting in occlusion (eg, embolism, Buerger's disease, vasculitis)
- •Subject is currently taking Canagliflozin
- •Body Mass Index (BMI) <18
- •Active septicemia or bacteremia
- •Coagulation disorder, including hypercoagulability
- •Contraindication to anticoagulation or antiplatelet therapy
- •Known allergies to stent or stent components
- •Known allergy to contrast media that cannot be adequately pre-medicated prior to the interventional procedure
- •Known hypersensitivity to heparin
- •Subject is on a high dose of steroids or is on immunosuppressive therapy
- •Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Concept Medical study team)
- •Intraoperative exclusion criteria
- •Angiographic evidence of intra-arterial acute/subacute thrombus or presence of atheroembolism
- •Treatment required in > 2 target vessels (Note: a target lesion originating in one vessel and extending into another vessel is considered 1 target vessel)
- •Treatment requires the use of alternate therapy in the target vessel(s)/lesion(s), (eg, atherectomy, cutting balloon, re-entry devices, laser, radiation therapy)
- •Aneurysm is present in the target vessel(s)
- •Extremely calcified lesions
- •Failure to obtain <30% residual stenosis in a pre-existing lesion
结局指标
主要结局
Primary patency using duplex ultrasound at 6 months post-procedure
时间窗: at 6 months post-procedure
Number of Primary patency using duplex ultrasound at 6 months post-procedure
Major adverse events (MAE) at 6 months post-procedure
时间窗: at 6 months post-procedure
Number of Major adverse events (MAE) (MAE is defined as above ankle amputation in index limb; major re-intervention; and perioperative (30 day) mortality)
次要结局
- Rutherford classification(3, 6, 12, 24 months post procedure)
- Adverse Events(1, 3, 6, 12, 24 months post procedure)
- Hemodynamic outcomes(6 and 12 months post procedure)
- Major amputation rates(1, 3, 6, 12, 24 months post procedure)
- Unplanned hospital readmission(Up to 30 days post procedure)
- Primary and assisted primary patency(6, 12, 24 months post procedure)
- All Cause Mortality(6, 12, 24 months years post procedure)
- Clinically driven target lesion revascularization(1, 3, 6, 12, 24 months post procedure)
- Wound Assessment(1, 3, 6, 12, 24 months post procedure)
- Subject quality-of-life values by change in EQ-5D (EuroQol 5 dimension)(1, 3, 6 and 12 months post procedure)